Patents by Inventor Rajesh Kotcherlakota

Rajesh Kotcherlakota has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Gold nanoparticle based formulation for use in cancer therapy
    Patent number: 10806715
    Abstract: The current invention relates to development of new formulation containing gold nanoparticles (AuNPs) with bi-functional recombinant fusion proteins TRAF(C) for the delivery of anticancer drugs and nucleic acids to HER2+ cancers. Using the combinatorial approach, we designed gold nanoparticle-based targeted drug delivery system (TDDS) or (Au-TR-DX-si) by combining AuNPs with bi-functional recombinant fusion protein TRAF(C) (TR), doxorubicin (DX) and siRNA (si). The recombinant protein based gold nanoparticles formulations are stable and homogenous as revealed by several physicochemical studies. In addition, the engineered fusion protein TRAF (C) has the ability to target selectively to HER2+ receptors overexpressed in ovarian cancer cells (SK-OV-3).
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: October 20, 2020
    Assignee: Council of Scientific & Industrial Research
    Inventors: Rajesh Kotcherlakota, Sudip Mukherjee, Chitta Ranjan Patra, Vijaya Gopal
  • GOLD NANOPARTICLE BASED FORMULATION FOR USE IN CANCER THERAPY
    Publication number: 20190240186
    Abstract: The current invention relates to development of new formulation containing gold nanoparticles (AuNPs) with bi-functional recombinant fusion proteins TRAF(C) for the delivery of anticancer drugs and nucleic acids to HER2+ cancers. Using the combinatorial approach, we designed gold nanoparticle-based targeted drug delivery system (TDDS) or (Au-TR-DX-si) by combining AuNPs with bi-functional recombinant fusion protein TRAF(C) (TR), doxorubicin (DX) and siRNA (si). The recombinant protein based gold nanoparticles formulations are stable and homogenous as revealed by several physicochemical studies. In addition, the engineered fusion protein TRAF (C) has the ability to target selectively to HER2+ receptors overexpressed in ovarian cancer cells (SK-OV-3).
    Type: Application
    Filed: October 23, 2017
    Publication date: August 8, 2019
    Inventors: Rajesh Kotcherlakota, Sudip Mukherjee, Chitta Ranjan Patra, Vijaya Gopal